Bupranolol

Bupranolol

Clinical data
AHFS/Drugs.com	International Drug Names
Routes of administration	Oral, topical (eye drops)
ATC code	C07AA19 (WHO)
Pharmacokinetic data
Bioavailability	< 10%
Protein binding	76%
Metabolism	First pass elimination > 90%
Elimination half-life	2-4 hours (plasma)
Excretion	> 88% renal (as carboxybupranolol)
Identifiers
IUPAC name (RS)-1-(tert-butylamino)-3-(2-chloro-5-methylphenoxy)propan-2-ol
CAS Number	23284-25-5 N
PubChem CID	2475
IUPHAR/BPS	550
DrugBank	DB08808 Y
ChemSpider	2381 Y
UNII	858YGI5PIT
KEGG	D07590 N
ChEMBL	ChEMBL305380 Y
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C14H22ClNO2
Molar mass	271.78298 g/mol
3D model (JSmol)	Interactive image
SMILES CC1=CC(=C(C=C1)Cl)OCC(CNC(C)(C)C)O
InChI InChI=1S/C14H22ClNO2/c1-10-5-6-12(15)13(7-10)18-9-11(17)8-16-14(2,3)4/h5-7,11,16-17H,8-9H2,1-4H3 Y Key:HQIRNZOQPUAHHV-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

WikiDoc Resources for Bupranolol
Articles
Most recent articles on Bupranolol Most cited articles on Bupranolol Review articles on Bupranolol Articles on Bupranolol in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Bupranolol Images of Bupranolol Photos of Bupranolol Podcasts & MP3s on Bupranolol Videos on Bupranolol
Evidence Based Medicine
Cochrane Collaboration on Bupranolol Bandolier on Bupranolol TRIP on Bupranolol
Clinical Trials
Ongoing Trials on Bupranolol at Clinical Trials.gov Trial results on Bupranolol Clinical Trials on Bupranolol at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Bupranolol NICE Guidance on Bupranolol NHS PRODIGY Guidance FDA on Bupranolol CDC on Bupranolol
Books
Books on Bupranolol
News
Bupranolol in the news Be alerted to news on Bupranolol News trends on Bupranolol
Commentary
Blogs on Bupranolol
Definitions
Definitions of Bupranolol
Patient Resources / Community
Patient resources on Bupranolol Discussion groups on Bupranolol Patient Handouts on Bupranolol Directions to Hospitals Treating Bupranolol Risk calculators and risk factors for Bupranolol
Healthcare Provider Resources
Symptoms of Bupranolol Causes & Risk Factors for Bupranolol Diagnostic studies for Bupranolol Treatment of Bupranolol
Continuing Medical Education (CME)
CME Programs on Bupranolol
International
Bupranolol en Espanol Bupranolol en Francais
Business
Bupranolol in the Marketplace Patents on Bupranolol
Experimental / Informatics
List of terms related to Bupranolol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Bupranolol is a non-selective beta blocker without intrinsic sympathomimetic activity (ISA), but with strong membrane stabilizing activity. Its potency is similar to propranolol.

Uses and Dosage

Like other beta blockers, oral bupranolol can be used to treat hypertension and tachycardia. The initial dose is 50 mg two times a day. It can be increased to 100 mg four times a day. Bupranolol eye drops (0.05%-0.5%) are used against glaucoma.

Pharmacology

Bupranolol is quickly and completely absorbed from the gut. Over 90% undergo first-pass metabolism. Bupranolol has a plasma half life of about two to four hours, with levels never reaching 1 µg/l in therapeutic doses. The main metabolite is carboxybupranolol, 4-chloro-3-[3-(1,1-dimethylethylamino)-2-hydroxy-propyloxy]benzoic acid – that is, the methyl group at the benzene ring is oxidized to a carboxyl group –, of which 88% are eliminated renally within 24 hours.

Adverse Effects, Contraindications, Interactions

Adverse effects, contraindications and interactions are similar to other beta blockers.